Clinical research
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 29, 2020.
San Francisco-based Audentes Therapeutics reported two deaths in its gene therapy clinical trial. The therapy, AT132, is for X-linked myotubular myopathy.
It was a busy week for clinical trial updates. Here’s a look.
With Moderna on the precipice of launching its Phase III trial of 30,000 people for its COVID-19 vaccine, mRNA-1273, it is ramping up manufacturing capabilities.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.
Shares of Fulcrum Therapeutics were up more than 14% in premarket trading after the company announced it will begin the Phase LOSVID III study to assess losmapimod as a potential treatment of COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
Relugolix is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist.
With phase III trials underway and Fast Track designation from the FDA, “It’s, conservatively, at least one year ahead of everyone else’s,” John Temperato, president and CEO, told BioSpace.
Ridgeback Therapeutics will launch two mid-stage programs assessing the efficacy of its antiviral candidate EIDD-2801 as a treatment for COVID-19.
PRESS RELEASES